Literature DB >> 3451884

Role of heart rate reduction in the treatment of exercise-induced myocardial ischaemia.

B D Guth1, G Heusch, R Seitelberger, M Matsuzaki, J Ross.   

Abstract

The role of bradycardia in reducing exercise-induced ischaemia and wall dysfunction was examined in dogs with single vessel chronic coronary artery stenosis created using an ameroid constrictor. Treadmill exercise produced significant regional myocardial ischaemia (blood flow measured using microspheres) and contractile dysfunction (systolic wall thickening measured with sonomicrometers). Dogs were initially studied during a control run before and during a second identical run after administration of the cardioselective beta-adrenergic blocker atenolol, which improved regional ischaemic function from 4.4 +/- 3.7% to 8.5 +/- 2.8% and subendocardial perfusion from 0.43 +/- 0.23 to 0.55 +/- 0.29 ml min-1 g-1. In another group of dogs during a run with atenolol, the heart rate was paced to match the rate observed in the control run. During the atenolol run with pacing, all beneficial effects of atenolol observed at the reduced exercise heart rate were lost. A third group of dogs received the bradycardic agent UL-FS 49 (1.0 mg kg-1, i.v.) prior to exercise. UL-FS 49 produced a heart rate reduction during exercise from 230 +/- 19 to 139 +/- 10 beats min-1; this was associated with an increase in systolic wall thickening from 9.3 +/- 5.0% (during the control run) to 21.5 +/- 8.4%, thereby eliminating the exercise-induced contractile dysfunction. Transmural myocardial blood flow per beat to the poststenotic myocardium was improved significantly from 4.8 X 10(-3) +/- 1.9 X 10(-3) ml beat-1 to 9.8 X 10(-3) +/- 1.7 X 10(-3). Atrial pacing to match heart rate to the control exercise rate during the UL-FS 49 run did not eliminate all of the improvement in systolic wall thickening.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3451884     DOI: 10.1093/eurheartj/8.suppl_l.61

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

1.  Effects of atenolol, slow-release nifedipine, and their combination on respiratory gas exchange and exercise tolerance in stable effort angina.

Authors:  S Wieshammer; M Hetzel; U Barnikel; M Höher; H Seibold; M Kochs; V Hombach
Journal:  Klin Wochenschr       Date:  1991-09-16

2.  Heart rate in coronary artery disease: should we lower it?

Authors:  Kelly Axsom; Sripal Bangalore
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

Review 3.  Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention.

Authors:  Cosmo Godino; Antonio Colombo; Alberto Margonato
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

4.  On the mechanism of the "specific bradycardic action" of the verapamil derivative UL-FS 49.

Authors:  T Doerr; W Trautwein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-04       Impact factor: 3.000

5.  The haemodynamic actions of ZENECA ZD7288, a novel sino-atrial node function modulator, in the exercising beagle: a comparison with zatebradine and propranolol.

Authors:  W Rouse; P J Stafford; I R Johnson
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

Review 6.  Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents.

Authors:  G Heusch
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.